323 related articles for article (PubMed ID: 25544641)
1. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
Petzer JP; Petzer A
Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641
[TBL] [Abstract][Full Text] [Related]
2. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
[TBL] [Abstract][Full Text] [Related]
3. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
Petzer JP; Castagnoli N; Schwarzschild MA; Chen JF; Van der Schyf CJ
Neurotherapeutics; 2009 Jan; 6(1):141-51. PubMed ID: 19110205
[TBL] [Abstract][Full Text] [Related]
4.
Boulaamane Y; Ibrahim MAA; Britel MR; Maurady A
J Integr Bioinform; 2022 Dec; 19(4):. PubMed ID: 36112816
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC).
Vlok N; Malan SF; Castagnoli N; Bergh JJ; Petzer JP
Bioorg Med Chem; 2006 May; 14(10):3512-21. PubMed ID: 16442801
[TBL] [Abstract][Full Text] [Related]
6. Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.
Cruz-Monteagudo M; Borges F; Cordeiro MNDS; Helguera AM; Tejera E; Paz-Y-Mino C; Sanchez-Rodriguez A; Perera-Sardina Y; Perez-Castillo Y
Curr Neuropharmacol; 2017 Nov; 15(8):1117-1135. PubMed ID: 28093976
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.
Pretorius J; Malan SF; Castagnoli N; Bergh JJ; Petzer JP
Bioorg Med Chem; 2008 Sep; 16(18):8676-84. PubMed ID: 18723354
[TBL] [Abstract][Full Text] [Related]
8. 8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors.
Brunschweiger A; Koch P; Schlenk M; Rafehi M; Radjainia H; Küppers P; Hinz S; Pineda F; Wiese M; Hockemeyer J; Heer J; Denonne F; Müller CE
Bioorg Med Chem; 2016 Nov; 24(21):5462-5480. PubMed ID: 27658798
[TBL] [Abstract][Full Text] [Related]
9. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Koch P; Akkari R; Brunschweiger A; Borrmann T; Schlenk M; Küppers P; Köse M; Radjainia H; Hockemeyer J; Drabczyńska A; Kieć-Kononowicz K; Müller CE
Bioorg Med Chem; 2013 Dec; 21(23):7435-52. PubMed ID: 24139167
[TBL] [Abstract][Full Text] [Related]
10. Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson's Disease Dual Target Ligands.
Perez-Castillo Y; Helguera AM; Cordeiro MNDS; Tejera E; Paz-Y-Mino C; Sanchez-Rodriguez A; Borges F; Cruz-Monteagudo M
Curr Neuropharmacol; 2017 Nov; 15(8):1107-1116. PubMed ID: 28067172
[TBL] [Abstract][Full Text] [Related]
11. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism.
Chen JF; Steyn S; Staal R; Petzer JP; Xu K; Van Der Schyf CJ; Castagnoli K; Sonsalla PK; Castagnoli N; Schwarzschild MA
J Biol Chem; 2002 Sep; 277(39):36040-4. PubMed ID: 12130655
[TBL] [Abstract][Full Text] [Related]
12. Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.
Załuski M; Schabikowski J; Schlenk M; Olejarz-Maciej A; Kubas B; Karcz T; Kuder K; Latacz G; Zygmunt M; Synak D; Hinz S; Müller CE; Kieć-Kononowicz K
Bioorg Med Chem; 2019 Apr; 27(7):1195-1210. PubMed ID: 30808606
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson's Disease.
Wang X; Han C; Xu Y; Wu K; Chen S; Hu M; Wang L; Ye Y; Ye F
Molecules; 2017 Jun; 22(6):. PubMed ID: 28629145
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues.
Petzer A; Grobler P; Bergh JJ; Petzer JP
J Pharm Pharmacol; 2014 May; 66(5):677-87. PubMed ID: 24313346
[TBL] [Abstract][Full Text] [Related]
15. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
Stössel A; Schlenk M; Hinz S; Küppers P; Heer J; Gütschow M; Müller CE
J Med Chem; 2013 Jun; 56(11):4580-96. PubMed ID: 23631427
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
Petzer JP; Steyn S; Castagnoli KP; Chen JF; Schwarzschild MA; Van der Schyf CJ; Castagnoli N
Bioorg Med Chem; 2003 Apr; 11(7):1299-310. PubMed ID: 12628657
[TBL] [Abstract][Full Text] [Related]
18. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
Schapira AH
CNS Drugs; 2011 Dec; 25(12):1061-71. PubMed ID: 22133327
[TBL] [Abstract][Full Text] [Related]
19. The adenosine A(2A) antagonistic properties of selected C8-substituted xanthines.
Van der Walt MM; Terre'Blanche G; Petzer A; Lourens AC; Petzer JP
Bioorg Chem; 2013 Aug; 49():49-58. PubMed ID: 23892098
[TBL] [Abstract][Full Text] [Related]
20. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.
Castagnoli N; Petzer JP; Steyn S; Castagnoli K; Chen JF; Schwarzschild MA; Van der Schyf CJ
Neurology; 2003 Dec; 61(11 Suppl 6):S62-8. PubMed ID: 14663013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
